Relief Therapeutics Holding AG (RLFTD) Stock Analysis

Relief Therapeutics Holding AG (RLFTD) Healthcare & Pipeline Overview

Relief Therapeutics Holding AG is a clinical-stage biopharmaceutical company developing therapies for respiratory diseases and rare genetic disorders. Its lead drug candidate, RLF-100 (aviptadil), is in Phase 3 trials for COVID-19-induced respiratory distress. The company operates in the competitive biotechnology sector, focusing on unmet medical needs.

What Is the Investment Thesis for RLFTD?

Relief Therapeutics presents a high-risk, high-reward investment profile characteristic of clinical-stage biopharmaceutical companies. The primary value driver is the successful completion of Phase 3 trials for RLF-100 (aviptadil) in COVID-19-related respiratory distress, a market with significant potential, though diminishing due to vaccines and treatments. Positive data and regulatory approvals could lead to substantial revenue. However, the company faces significant clinical and regulatory risks. The success of ACER-001 and APR-TD011 in their respective trials also contributes to the investment thesis. The company's relatively small market capitalization of $44.9M reflects these risks and uncertainties. Investors should closely monitor clinical trial results and regulatory developments.

Based on FMP financials and quantitative analysis

RLFTD Key Highlights

RLF-100 (aviptadil) is in Phase 3 clinical trials for COVID-19-induced acute respiratory distress syndrome.

• ACER-001 has completed Phase 3 clinical trials for urea cycle disorders.
• APR-TD011 is in Phase 2 clinical trial for treating epidermolysis bullosa.
• The company focuses on molecules with a history of clinical use to accelerate development.
• Relief Therapeutics operates in Switzerland, Europe, North America, and internationally.

Who Are RLFTD's Competitors?

RLFTD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RLFTD's Key Strengths?

Lead compound (RLF-100) in Phase 3 trials.

• Focus on unmet medical needs.
• Experienced management team.
• Diverse pipeline of clinical-stage assets.

What Are RLFTD's Weaknesses?

Limited financial resources.

• High dependence on clinical trial outcomes.
• OTC market listing.
• Small market capitalization.

What Could Drive RLFTD Stock Higher?

RLFTD catalyst: Results from Phase 3 clinical trials for RLF-100 (aviptadil) in COVID-19-induced acute respiratory distress syndrome.

• Results from Phase 1 clinical trial for ACER-001 in Maple Syrup Urine Disease.
• Results from Phase 2 clinical trial for APR-TD011 in treating epidermolysis bullosa.
• Advancement of RLF-100 (aviptadil) into Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit.
• Regulatory review and potential approval of ACER-001 for urea cycle disorders.

What Are the Key Risks for RLFTD?

Financial-distress signal — its Altman Z-Score of -12.39 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-38.5%) — the business is not currently generating profit on shareholder capital.
• Failure of RLF-100 (aviptadil) in Phase 3 clinical trials.
• Regulatory rejection of ACER-001 for urea cycle disorders.
• Competition from other companies developing therapies for similar indications.
• Limited financial resources and dependence on future financing.
• Risks associated with operating in the OTC market.

What Are the Growth Opportunities for RLFTD?

• Expansion of RLF-100 (aviptadil) into new respiratory indications: Beyond COVID-19, aviptadil's mechanism of action could be applicable to other respiratory diseases, such as acute lung injury (ALI) from other causes. Successful Phase 1 trials for ALI in intensive care units could open a new market.
• Commercialization of ACER-001 for urea cycle disorders: Following the completion of Phase 3 clinical trials, ACER-001 has the potential to become a valuable treatment option for patients with urea cycle disorders (UCDs). UCDs are rare genetic conditions, and the market for UCD treatments is relatively small but underserved. Successful commercialization of ACER-001 could provide a steady revenue stream for Relief Therapeutics.
• Development of APR-TD011 for epidermolysis bullosa: APR-TD011, currently in Phase 2 clinical trials for epidermolysis bullosa (EB), represents another growth opportunity in a rare disease market. EB is a group of genetic skin disorders characterized by fragile skin that blisters easily. There is a significant unmet need for effective EB treatments, and APR-TD011 could address this need if clinical trials are successful.
• Strategic partnerships and collaborations: Relief Therapeutics can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. These partnerships could provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its therapies to market. Collaborations can also help to mitigate the financial risks associated with drug development.
• Geographic expansion into new markets: Relief Therapeutics currently operates in Switzerland, Europe, and North America. Expanding into new geographic markets, such as Asia and Latin America, could provide access to a larger patient population and increase revenue potential. However, geographic expansion requires careful planning and execution to navigate regulatory hurdles and establish effective distribution channels.

What Threats Does RLFTD Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from established pharmaceutical companies.
• Dilution from future equity financings.

What Are RLFTD's Competitive Advantages?

• Proprietary drug formulations and intellectual property protection.
• Clinical trial data demonstrating safety and efficacy.
• Focus on niche markets with unmet medical needs.
• Experienced management team with expertise in drug development.

What Does RLFTD Do?

Relief Therapeutics Holding AG, founded in 2013 and based in Geneva, Switzerland, is a biopharmaceutical company dedicated to providing therapeutic relief for patients suffering from serious diseases with high unmet medical needs. The company's strategy centers around clinical-stage programs based on molecules with a history of clinical use, leveraging existing human activity or efficacy data, or a strong scientific rationale to accelerate development. Their primary focus is on respiratory indications and rare genetic disorders. Relief's lead compound, RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP), is currently in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury. Additionally, aviptadil is in Phase 1 for acute lung injury in intensive care units and Phase 2 for pulmonary sarcoidosis. Beyond RLF-100, Relief is developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trials for urea cycle disorders and is in Phase 1 for maple syrup urine disease. APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, is in Phase 2 clinical trials for treating epidermolysis bullosa. Relief Therapeutics operates in Switzerland, the rest of Europe, North America, and internationally.

What Products and Services Does RLFTD Offer?

• Develops therapies for serious diseases with high unmet medical needs.
• Focuses on clinical-stage programs based on molecules with a history of clinical use.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approvals for its therapies from health authorities.
• Commercializes its approved therapies through partnerships or direct sales.
• Develops treatments for respiratory indications, urea cycle disorders and epidermolysis bullosa.

How Does RLFTD Make Money?

• Develops and patents novel therapeutic compounds.
• Outlicenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments and royalties on sales of partnered products.
• Funds research and development through equity financing and strategic collaborations.

What Industry Does RLFTD Operate In?

Relief Therapeutics operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The market for respiratory therapeutics is competitive, with established players and emerging companies vying for market share. The company's focus on rare genetic disorders provides opportunities in niche markets with less competition but also requires specialized expertise and patient outreach. The overall biotechnology industry is experiencing growth, driven by advancements in genomics, personalized medicine, and increasing demand for novel therapies. Competitors include ACOGF, ASSF, DMTTF, HRPMF, and LSBCF.

Who Are RLFTD's Key Customers?

• Patients suffering from COVID-19-induced acute respiratory distress syndrome.
• Patients with urea cycle disorders.
• Patients with epidermolysis bullosa.
• Healthcare providers who prescribe Relief Therapeutics' therapies.

Company Profile

Relief Therapeutics Holding AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Geneva, CH. The company is led by CEO Jack Weinstein. RLFTD has traded publicly since 2021.

Relief Therapeutics Holding AG's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -12.39 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Relief Therapeutics Holding AG stands at -38.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -41.4%, the inverse of the P/E and a quick read on earnings relative to price.

RLFTD Valuation & Market Position

With a $44.9M market cap, Relief Therapeutics Holding AG sits in the micro-cap segment of the market.

RLFTD Financials

RLFTD Latest News

No recent news available for RLFTD.

Common Questions About RLFTD (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources